Ultragenyx Pharmaceutical (RARE) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$418.2 million.
- Ultragenyx Pharmaceutical's Enterprise Value rose 3194.88% to -$418.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$418.2 million, marking a year-over-year increase of 3194.88%. This contributed to the annual value of -$603.0 million for FY2024, which is 447.26% down from last year.
- Per Ultragenyx Pharmaceutical's latest filing, its Enterprise Value stood at -$418.2 million for Q3 2025, which was up 3194.88% from -$480.6 million recorded in Q2 2025.
- In the past 5 years, Ultragenyx Pharmaceutical's Enterprise Value ranged from a high of -$412.1 million in Q1 2024 and a low of -$965.4 million during Q1 2021
- Moreover, its 5-year median value for Enterprise Value was -$603.0 million (2024), whereas its average is -$634.0 million.
- Per our database at Business Quant, Ultragenyx Pharmaceutical's Enterprise Value crashed by 4555.1% in 2021 and then soared by 5025.25% in 2023.
- Ultragenyx Pharmaceutical's Enterprise Value (Quarter) stood at -$740.2 million in 2021, then decreased by 1.02% to -$747.8 million in 2022, then grew by 22.81% to -$577.2 million in 2023, then decreased by 4.47% to -$603.0 million in 2024, then surged by 30.64% to -$418.2 million in 2025.
- Its Enterprise Value was -$418.2 million in Q3 2025, compared to -$480.6 million in Q2 2025 and -$487.4 million in Q1 2025.